Biomarkers of Inflammation in Cuban Children with SARS-Cov-2 Infection in Intensive Care, in San Miguel Del Padrón

Authors

  • Denise Bello González Hospital Pediátrico Docente de San Miguel del Padrón.La Habana.
  • Juan Carlos de la Torre Pérez
  • Fidel Ernesto Pérez Marrero
  • Lissette del Rosario López González
  • Dayana Francis Magdariaga Arrieta

Keywords:

SARS-CoV-2, COVID-19 in severe pediatric patients, biomarkers.

Abstract

Introduction: Patients with COVID-19 disease may present different symptoms and health problems. The use of biomarkers makes it possible to interpret the progression of the disease, perform a more defined categorization of patients and intervene early. Objective: To describe the altered biomarkers in pediatric patients with COVID-19 in severe and critical condition. Methods: A retrospective, descriptive, cross-sectional cohort study was carried out in children diagnosed with COVID-19 in intensive care, from April 2020 to June 2021, from Havana. A total of 83 children were selected through non-probabilistic sampling. Results: Erythrocyte sedimentation rate and procalcitonin remained elevated at all ages and exceeded 70%. Interleukin was the third most representative analytical marker, with the highest incidence in patients between 15 and 18 years (61%). D-dimer was elevated in children under one year of age (50%). The neutrophil/lymphocyte ratio had higher incidence in adolescents (28%) and ferritin in those under one year of age (25%). Conclusions: The inflammation markers that stood out in the research were erythrocyte sedimentation rate, procalcitonin, interleukin, D-dimer, neutrophil/lymphocyte ratio and ferritin. Erythrocyte sedimentation rate, procalcitonin and D-dimer had a higher incidence in critically ill patients. In these children, the average values that reached the highest values were ferritin, erythrocyte sedimentation rate and procalcitonin.

Downloads

Download data is not yet available.

Author Biography

Denise Bello González, Hospital Pediátrico Docente de San Miguel del Padrón.La Habana.

Servicio de Terapia Intensiva Pediátrica. Especialista I grado en Terapia Intensiva y Emergencias Pediátricas. Profesor asistente.

References

1. Cervera R, Espinosa G, Ramos M, Hernández J, Prieto S. Espígol G, et al. Respuesta inmunoinflamatoria en la COVID-19. En: Enfermedades autoinmunes sistémicas. Diagnóstico y tratamiento. 6 ed. Madrid: Editorial Médica Panamericana; 2021 [acceso 20/05/2021]. Disponible en: https://www.medicapanamericana.com/es/libro/respuesta-inmunoinflamatoria-en-la-covid-19

2. Wu Z, McGoogan JM. Characteristics of an important lesson from the coronavirus disease (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. DOI: https://doi.org/10.100//jama.2020.2648

3. Márquez MP, Gutiérrez A, Lizárraga SL, Muñoz CM, Ventura ST, Zárate PMS, et al. Espectro clínico de COVID-19, enfermedad en el paciente pediátrico. Acta Pediatr Mex. 2020 [acceso 20/05/2021];41(1):64-71. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=94518

4. Geng L, Yaohuao F, Yanni L, Tiantian H, Zonghui L. Coronavirus Infections and Immune Responses. J Med Virol. 2020;92:424-32. DOI: https://doi.org/10.1002/jmv.25685

5. Parisi GF, Indolfi C, Decimo F, Leonardi S, Miraglia del Giudice M. Neumonía por COVID-19 en niños: De su etiología a su manejo. Kompass Neumol. 2021;3(2). DOI: https://doi.org/10.1159/000516059

6. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. J Emerg Med. 2020;58(4):712-3 DOI: https://doi.org/10.1016/j.jemermed.2020.04.006

7. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355-68. DOI: https://doi.org/10.1097/INF.0000000000002660

8. Iñiguez L, Figueroa E, Germán AM, López LR, Somarriba L. La COVID-19 en niños y adolescentes cubanos. Noveno reporte. Semanas epidemiológicas de la 44 a la 52 de 2021. Del 31 de octubre del 2021 al 1 de enero del 2022. La Habana: Oficina Nacional de Estadísticas e Información; 2022 [acceso 20/01/2022]. Disponible en: https://www.unicef.org/cuba/media/4006/file/COVID-19_I.9%20NNA%20cubanos.pdf%20.pdf

9. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur Surveill. 2020;25(3). DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

10. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6). DOI: https://doi.org/10.1002/ajh.25774

11. Lapić I, Rogić D, Plebani M. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis. Clin Chem Lab Med. 2020 [acceso 20/5/2020];58(7):1146-8. DOI: https://doi.org/10.1515/cclm-2020-0620

12. Gutiérrez JC, Almonacid CC, Hernández EC, Mendieta H. Valor pronóstico de los marcadores bioquímicos en pacientes con COVID-19. Nova. 2020;18(35):51-8. DOI: https://doi.org/10.22490/24629448.4186

13. Califf R. Biomarker definitions and their applications. Exp Biol and Med. 2018;243(3):213-21. DOI: https://doi.org/10.1177/1535370217750088

14. Lai CC, Shih TP, Ko WC, Tan HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3). DOI: https://doi.org/10.1016/j.ijantimicag.2020.105924

15. Ipanaqué C, Hilario K, Huamán L, Jiménez Y, Julián-Guevara K, Isla F, et al. Biomarcadores asociados al pronóstico de formas severas y críticas de COVID-19 Rev Méd Trujillo. 2021;16(1):66-73. DOI: http://doi.org/10.17268/rmt.2020.v16i01.12

16. Letelier P, Encina N, Morales P, Riffo A, Silva H, Riquelme I, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem. 2021;40(2):115-28. DOI: https://doi.org/10.5937/jomb0-29341

17. Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a Risk Factor of Severe COVID-19 Patients: A Retrospective and Observational Study. MedRxiv. 2020;12(12). DOI: https://doi.org/10.1101/2020.03.24.20040162

18. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020;58(7):1095-9. DOI: http://doi.org/10.1515/cclm-2020-0398

19. Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, et al. The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis. Prog Cardiovasc Dis. 2020;63(4):518-24. DOI: http://doi.org/10.1016/j.pcad.2020.04.008

20. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337-42. DOI: http://doi.org/10.55563/clinexprheumatol/xcdary

21. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143-56. DOI: https://doi.org/10.1001/jamapediatrics.2020.4573

22. Protocolo de actuación nacional para la COVID-19. Versión 1.4 (Versión provisional para uso del personal de salud que labora en el enfrentamiento a los casos). La Habana: Ministerio de Salud Pública; 2020 [acceso 23/05/2020]. Disponible en: http://www.sld.cu/anuncio/2020/05/11/ministerio-de-salud-publica-protocolo-de-actuacion-nacional-para-la-covid-19

23. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):1-95. DOI: https://doi.org/10.1001/jama.2013.281053.

24. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020;71(6):1547-51. DOI: https://doi.org/10.1093/cid/ciaa198

25. Plasencia-Urizarri TM, Aguilera-Rodríguez R, Almaguer-Mederos LE. Comorbilidades y gravedad clínica de COVID-19: revisión sistemática y meta-análisis. Rev Habanera Cienc Méd. 2020 [acceso 01/10/2021];19(1). Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3389

26. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5. DOI: https://doi.org/10.1038/s41392-020-00243-2

27. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 2020;75(9):1788-95. DOI: https://doi.org/10.1093/gerona/glaa089

28. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8. DOI: https://doi.org/10.1515/cclm-2020-0369.

29. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2). DOI: https://doi.org/10.1016/j.ijantimicag.2020.106051

30. Guihot A, Litvinova E, Autran B, Debré P, Vieillard V. Cell-Mediated Immune Responses to COVID-19 Infection. Front Immunol. 2020;11. DOI: https://doi.org/10.3389%2Ffimmu.2020.01662

31. Huang G, Kovalic AJ, Graber CJ. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity. Emerg Infect Dis. 2020;26(8):1839-41. DOI: https://doi.org/10.3201/eid2608.201160

32. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. DOI: https://doi.org/10.1016/S22132600(20)30079-5

33. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7

34. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368. DOI: https://doi.org/10.1136/bmj.m1295

35. Pascual NF, Monge I, Granero I, Figuerola A, Ramasco F, von Wernitz A, et al. Potenciales biomarcadores predictores de mortalidad en pacientes COVID-19 en el Servicio de Urgencias. Rev Esp Quimioter. 2020;33(4):267-73. DOI: https://doi.org/10.37201/req/060.2020

Downloads

Published

2024-07-30

How to Cite

1.
Bello González D, de la Torre Pérez JC, Pérez Marrero FE, López González L del R, Magdariaga Arrieta DF. Biomarkers of Inflammation in Cuban Children with SARS-Cov-2 Infection in Intensive Care, in San Miguel Del Padrón. Rev Cubana Pediatría [Internet]. 2024 Jul. 30 [cited 2025 Jun. 15];96. Available from: https://revpediatria.sld.cu/index.php/ped/article/view/7291

Issue

Vol. 96 (2024): Publicación continua

Section

PEDIATRÍA INTENSIVA

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).